Cargando…
Risques viraux émergents en transfusion sanguine
During the last 20 years, the safety of blood products increased dramatically with regard to the infectious risk and notably to that represented by retroviruses (HIV and HTLV) and hepatitis B and C viruses. The aim of this review is to identify the residual and emergent viral threats that could be r...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Masson SAS.
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110867/ https://www.ncbi.nlm.nih.gov/pubmed/21414828 http://dx.doi.org/10.1016/j.tracli.2011.01.009 |
_version_ | 1783513155544023040 |
---|---|
author | Pozzetto, B. Garraud, O. |
author_facet | Pozzetto, B. Garraud, O. |
author_sort | Pozzetto, B. |
collection | PubMed |
description | During the last 20 years, the safety of blood products increased dramatically with regard to the infectious risk and notably to that represented by retroviruses (HIV and HTLV) and hepatitis B and C viruses. The aim of this review is to identify the residual and emergent viral threats that could be responsible for the occurring of new contaminations in the receivers of blood products. Beside many other viruses (HHV-8, erythrovirus B19, hepatitis A and E viruses…), a special attention has been paid to emerging arbovirus diseases (West Nile virus infection, dengue, chikungunya) that threaten to occur in the French metropolitan area following the implantation in Europe of the mosquito Aedes albopictus, the main vector of dengue and chikungunya in temperate regions. Another blood-linked risk, notably in United Kingdom and France, is the prion agent responsible for the variant form of the Creutzfeldt-Jakob disease. The review is concluded by a brief overview of the measures aimed to control these emergences, including the exclusion of at-risk donors, the diagnostic tests able to detect a specific agent, the leukocyte reduction of labile blood products, and the physical or chemical treatments aiming the nonspecific inactivation of infectious agents potentially present in blood without impairing significantly the physiological properties of blood compounds. The ability to control prospectively the new viral risks linked to blood products is a challenge for the preservation of the confidence of both clinicians and receivers in the safety of blood transfusion. |
format | Online Article Text |
id | pubmed-7110867 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71108672020-04-02 Risques viraux émergents en transfusion sanguine Pozzetto, B. Garraud, O. Transfus Clin Biol État De L'Art During the last 20 years, the safety of blood products increased dramatically with regard to the infectious risk and notably to that represented by retroviruses (HIV and HTLV) and hepatitis B and C viruses. The aim of this review is to identify the residual and emergent viral threats that could be responsible for the occurring of new contaminations in the receivers of blood products. Beside many other viruses (HHV-8, erythrovirus B19, hepatitis A and E viruses…), a special attention has been paid to emerging arbovirus diseases (West Nile virus infection, dengue, chikungunya) that threaten to occur in the French metropolitan area following the implantation in Europe of the mosquito Aedes albopictus, the main vector of dengue and chikungunya in temperate regions. Another blood-linked risk, notably in United Kingdom and France, is the prion agent responsible for the variant form of the Creutzfeldt-Jakob disease. The review is concluded by a brief overview of the measures aimed to control these emergences, including the exclusion of at-risk donors, the diagnostic tests able to detect a specific agent, the leukocyte reduction of labile blood products, and the physical or chemical treatments aiming the nonspecific inactivation of infectious agents potentially present in blood without impairing significantly the physiological properties of blood compounds. The ability to control prospectively the new viral risks linked to blood products is a challenge for the preservation of the confidence of both clinicians and receivers in the safety of blood transfusion. Elsevier Masson SAS. 2011-04 2011-03-16 /pmc/articles/PMC7110867/ /pubmed/21414828 http://dx.doi.org/10.1016/j.tracli.2011.01.009 Text en Copyright © 2011 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | État De L'Art Pozzetto, B. Garraud, O. Risques viraux émergents en transfusion sanguine |
title | Risques viraux émergents en transfusion sanguine |
title_full | Risques viraux émergents en transfusion sanguine |
title_fullStr | Risques viraux émergents en transfusion sanguine |
title_full_unstemmed | Risques viraux émergents en transfusion sanguine |
title_short | Risques viraux émergents en transfusion sanguine |
title_sort | risques viraux émergents en transfusion sanguine |
topic | État De L'Art |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110867/ https://www.ncbi.nlm.nih.gov/pubmed/21414828 http://dx.doi.org/10.1016/j.tracli.2011.01.009 |
work_keys_str_mv | AT pozzettob risquesvirauxemergentsentransfusionsanguine AT garraudo risquesvirauxemergentsentransfusionsanguine |